tiprankstipranks
Biogen (BIIB)
NASDAQ:BIIB
US Market
BIIB
Biogen
RESEARCH TOOLSreports
Want to see BIIB full AI Analyst Report?

Biogen (BIIB) Stock Forecast & Price Target

5,023 Followers
See the Price Targets and Ratings of:

BIIB Analyst Ratings

Moderate Buy
26Ratings
Moderate Buy
15 Buy
10 Hold
1 Sell
Based on 26 analysts giving stock ratings to
Biogen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BIIB Stock 12 Month Forecast

Average Price Target

$218.76
▲(23.35% Upside)
Based on 26 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $218.76 with a high forecast of $275.00 and a low forecast of $150.00. The average price target represents a 23.35% change from the last price of $177.35.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"119":"$119","276":"$276","158.25":"$158.3","197.5":"$197.5","236.75":"$236.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":275,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$275.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":218.76190476190476,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$218.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":150,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$150.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[119,158.25,197.5,236.75,276],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,187.06,193.82461538461538,200.58923076923077,207.35384615384615,214.11846153846153,220.8830769230769,227.6476923076923,234.4123076923077,241.17692307692306,247.94153846153847,254.70615384615382,261.47076923076924,268.23538461538465,{"y":275,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,187.06,189.49860805860806,191.9372161172161,194.37582417582416,196.81443223443225,199.2530402930403,201.69164835164835,204.1302564102564,206.56886446886446,209.00747252747252,211.4460805860806,213.88468864468865,216.3232967032967,{"y":218.76190476190476,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,187.06,184.20923076923077,181.35846153846154,178.5076923076923,175.65692307692308,172.80615384615385,169.95538461538462,167.10461538461539,164.25384615384615,161.40307692307692,158.5523076923077,155.70153846153846,152.85076923076923,{"y":150,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":120.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.63,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.22,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.78,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.05,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.78,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.06,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$275.00Average Price Target$218.76Lowest Price Target$150.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on BIIB
David Amsellem
Piper Sandler
Piper Sandler
$214→$225
Buy
26.87%
Upside
Reiterated
05/15/26
Biogen price target raised to $225 from $214 at Piper SandlerBiogen price target raised to $225 from $214 at Piper Sandler
Wedbush Analyst forecast on BIIB
Laura Chico
Wedbush
Wedbush
$196
Hold
10.52%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (NASDAQ: KROS), Cormedix (NASDAQ: CRMD) and Biogen (NASDAQ: BIIB)
Truist Financial Analyst forecast on BIIB
Danielle Brill
Truist Financial
Truist Financial
―
Hold
―
Reiterated
05/15/26
Analysts Conflicted on These Healthcare Names: Aquestive Therapeutics (NASDAQ: AQST), Pyxis Oncology (NASDAQ: PYXS) and Biogen (NASDAQ: BIIB)
Goldman Sachs Analyst forecast on BIIB
Salveen Richter
Goldman Sachs
Goldman Sachs
$238→$250
Buy
40.96%
Upside
Reiterated
05/15/26
Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250
Canaccord Genuity Analyst forecast on BIIB
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$245
Buy
38.14%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB), Sol-Gel Technologies (NASDAQ: SLGL) and Aveanna Healthcare Holdings (NASDAQ: AVAH)
Evercore ISI Analyst forecast on BIIB
Umer Raffat
Evercore ISI
Evercore ISI
―
Buy
―
Initiated
05/15/26
Biogen resumed with an Outperform at Evercore ISIBiogen resumed with an Outperform at Evercore ISI
UBS Analyst forecast on BIIB
Michael Yee
UBS
UBS
$225
Buy
26.87%
Upside
Reiterated
05/15/26
Biogen Buy Rating Reiterated as Tau Data Eases Overhang; Price Target Maintained at $225
Needham Analyst forecast on BIIB
Ami Fadia
Needham
Needham
―
Hold
―
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: Kairos Pharma, Ltd. (NYSE MKT: KAPA), Integra Lifesciences (NASDAQ: IART) and Biogen (NASDAQ: BIIB)
William Blair Analyst forecast on BIIB
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
05/14/26
Minter Reiterates Buy on Biogen as Tau-Targeting Diranersen Data Signals Clinically Meaningful Cognitive Benefit and Strong Biomarker Validation
H.C. Wainwright Analyst forecast on BIIB
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$237
Buy
33.63%
Upside
Reiterated
05/14/26
Biogen Buy Rating Reiterated as CELIA Phase 2 Diranersen Data De-Risk Tau Strategy and Support Unchanged $237 Price Target
Bank of America Securities Analyst forecast on BIIB
Jason Zemansky
Bank of America Securities
Bank of America Securities
$203
Hold
14.46%
Upside
Reiterated
05/14/26
Biogen Rated Hold as Analyst Cites Mixed Alzheimer’s Data and Commercial Hurdles; $203 Price Target Reiterated
RBC Capital Analyst forecast on BIIB
Brian Abrahams
RBC Capital
RBC Capital
$222
Buy
25.18%
Upside
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO), Biogen (NASDAQ: BIIB) and COMPASS Pathways (NASDAQ: CMPS)
TD Cowen Analyst forecast on BIIB
Phil Nadeau
TD Cowen
TD Cowen
$215
Buy
21.23%
Upside
Reiterated
05/14/26
TD Cowen Sticks to Their Buy Rating for Biogen (BIIB)
Wells Fargo Analyst forecast on BIIB
Mohit Bansal
Wells Fargo
Wells Fargo
$250
Buy
40.96%
Upside
Assigned
05/14/26
Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), RegenXBio (RGNX)
Morgan Stanley Analyst forecast on BIIB
Terence Flynn
Morgan Stanley
Morgan Stanley
$206
Hold
16.15%
Upside
Reiterated
05/14/26
Hold Rating Maintained on Biogen as BIIB080 Moves to Phase 3; Risk-Reward Seen Balanced with Unchanged $206 Price Target
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on BIIB
David Amsellem
Piper Sandler
Piper Sandler
$214→$225
Buy
26.87%
Upside
Reiterated
05/15/26
Biogen price target raised to $225 from $214 at Piper SandlerBiogen price target raised to $225 from $214 at Piper Sandler
Wedbush Analyst forecast on BIIB
Laura Chico
Wedbush
Wedbush
$196
Hold
10.52%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (NASDAQ: KROS), Cormedix (NASDAQ: CRMD) and Biogen (NASDAQ: BIIB)
Truist Financial Analyst forecast on BIIB
Danielle Brill
Truist Financial
Truist Financial
―
Hold
―
Reiterated
05/15/26
Analysts Conflicted on These Healthcare Names: Aquestive Therapeutics (NASDAQ: AQST), Pyxis Oncology (NASDAQ: PYXS) and Biogen (NASDAQ: BIIB)
Goldman Sachs Analyst forecast on BIIB
Salveen Richter
Goldman Sachs
Goldman Sachs
$238→$250
Buy
40.96%
Upside
Reiterated
05/15/26
Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250
Canaccord Genuity Analyst forecast on BIIB
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$245
Buy
38.14%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB), Sol-Gel Technologies (NASDAQ: SLGL) and Aveanna Healthcare Holdings (NASDAQ: AVAH)
Evercore ISI Analyst forecast on BIIB
Umer Raffat
Evercore ISI
Evercore ISI
―
Buy
―
Initiated
05/15/26
Biogen resumed with an Outperform at Evercore ISIBiogen resumed with an Outperform at Evercore ISI
UBS Analyst forecast on BIIB
Michael Yee
UBS
UBS
$225
Buy
26.87%
Upside
Reiterated
05/15/26
Biogen Buy Rating Reiterated as Tau Data Eases Overhang; Price Target Maintained at $225
Needham Analyst forecast on BIIB
Ami Fadia
Needham
Needham
―
Hold
―
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: Kairos Pharma, Ltd. (NYSE MKT: KAPA), Integra Lifesciences (NASDAQ: IART) and Biogen (NASDAQ: BIIB)
William Blair Analyst forecast on BIIB
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
05/14/26
Minter Reiterates Buy on Biogen as Tau-Targeting Diranersen Data Signals Clinically Meaningful Cognitive Benefit and Strong Biomarker Validation
H.C. Wainwright Analyst forecast on BIIB
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$237
Buy
33.63%
Upside
Reiterated
05/14/26
Biogen Buy Rating Reiterated as CELIA Phase 2 Diranersen Data De-Risk Tau Strategy and Support Unchanged $237 Price Target
Bank of America Securities Analyst forecast on BIIB
Jason Zemansky
Bank of America Securities
Bank of America Securities
$203
Hold
14.46%
Upside
Reiterated
05/14/26
Biogen Rated Hold as Analyst Cites Mixed Alzheimer’s Data and Commercial Hurdles; $203 Price Target Reiterated
RBC Capital Analyst forecast on BIIB
Brian Abrahams
RBC Capital
RBC Capital
$222
Buy
25.18%
Upside
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO), Biogen (NASDAQ: BIIB) and COMPASS Pathways (NASDAQ: CMPS)
TD Cowen Analyst forecast on BIIB
Phil Nadeau
TD Cowen
TD Cowen
$215
Buy
21.23%
Upside
Reiterated
05/14/26
TD Cowen Sticks to Their Buy Rating for Biogen (BIIB)
Wells Fargo Analyst forecast on BIIB
Mohit Bansal
Wells Fargo
Wells Fargo
$250
Buy
40.96%
Upside
Assigned
05/14/26
Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), RegenXBio (RGNX)
Morgan Stanley Analyst forecast on BIIB
Terence Flynn
Morgan Stanley
Morgan Stanley
$206
Hold
16.15%
Upside
Reiterated
05/14/26
Hold Rating Maintained on Biogen as BIIB080 Moves to Phase 3; Risk-Reward Seen Balanced with Unchanged $206 Price Target
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biogen

3 Months
xxx
Success Rate
14/25 ratings generated profit
56%
Average Return
+1.08%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 56.00% of your transactions generating a profit, with an average return of +1.08% per trade.
1 Year
Myles MinterWilliam Blair
Success Rate
12/22 ratings generated profit
55%
Average Return
+11.34%
Copying Myles Minter's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +11.34% per trade.
2 Years
xxx
Success Rate
13/25 ratings generated profit
52%
Average Return
+1.16%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 52.00% of your transactions generating a profit, with an average return of +1.16% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BIIB Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
0
0
0
0
Buy
18
24
22
31
36
Hold
21
31
38
40
38
Sell
2
2
1
1
1
Strong Sell
0
0
0
0
0
total
41
57
61
72
75
In the current month, BIIB has received 36 Buy Ratings, 38 Hold Ratings, and 1 Sell Ratings. BIIB average Analyst price target in the past 3 months is 218.76.
Each month's total comprises the sum of three months' worth of ratings.

BIIB Financial Forecast

BIIB Earnings Forecast

Next quarter’s earnings estimate for BIIB is $3.18 with a range of $2.33 to $4.26. The previous quarter’s EPS was $3.57. BIIB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.
Next quarter’s earnings estimate for BIIB is $3.18 with a range of $2.33 to $4.26. The previous quarter’s EPS was $3.57. BIIB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.

BIIB Sales Forecast

Next quarter’s sales forecast for BIIB is $2.43B with a range of $2.21B to $2.66B. The previous quarter’s sales results were $2.40B. BIIB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.
Next quarter’s sales forecast for BIIB is $2.43B with a range of $2.21B to $2.66B. The previous quarter’s sales results were $2.40B. BIIB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.

BIIB Stock Forecast FAQ

What is BIIB’s average 12-month price target, according to analysts?
Based on analyst ratings, Biogen’s 12-month average price target is 218.76.
    What is BIIB’s upside potential, based on the analysts’ average price target?
    Biogen has 23.35% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BIIB a Buy, Sell or Hold?
          Biogen has a consensus rating of Moderate Buy which is based on 15 buy ratings, 10 hold ratings and 1 sell ratings.
            What is Biogen’s price target?
            The average price target for Biogen is 218.76. This is based on 26 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $275.00 ,the lowest forecast is $150.00. The average price target represents 23.35% Increase from the current price of $177.35.
              What do analysts say about Biogen?
              Biogen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 26 Wall Streets Analysts.
                How can I buy shares of BIIB?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.